Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q4 FY2025 Earnings Presentation
16 slides from Dr. Reddy's Laboratories's earnings presentation, May 12, 2025
Slide 1: Q4 & FY25 Financial Results
Q4 & FY25 FINANCIAL RESULTS = a Es i 1 Dr.Reddy’s Qs
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Q4 and FY25 Performance
Q4 Performance 78,506 cr Revenues 20%YoY = 2% QoQ 22,475 cr|29% EBITDA | EBITDA % 32%YoY 8% QoQ 22,005 cr|24% PBT | PBT % 1 25%Y0Y 7 7% QoQ 21,5944 cr| 19% PAT | PAT % 1 22%YoY “13% Q0Q ‘after adjusting for minority interest FY25 Performance 232,554 cr Revenues 47%YOY 29,213 cri 28% EBITDA | EBITDA
Slide 4: Continued progress on our priorities, in line with stated strategy
Continued progress on our priorities, in line with stated strategy KEY HIGHLIGHTS = UK integration completed in May’25 for acquired Nicotine Replacement Therapy (NRT) CD = Partnered with Henlius for exclusive commercialization rights of daratumumab biosimilar for the US & Europe @ Henlius BAR BIO-TH
Slide 5: Recognitions for our continued efforts in sustainability
Recognitions for our continued efforts in sustainability KEY HIGHLIGHTS ecovadis = EcoVadis score @73, among top 15% assessed globally = ‘CSR Program of the Year’ at Financial Express —- Pharma Awards 2025 PHARMA = Cll’s ‘Climate Action Program 2.0° Award’ in ‘Resilient’ category - Light Manufacturi
Slide 6: Q4: Overall double-digit growth driven by performance across geographies
Q4 : Overall double-digit growth driven by performance across geographies, aided by Consumer healthcare (NRT) revenues Q4 REVENUE BY SEGMENT GLOBAL GENERICS SPLIT IN Q4 3,559 cr GLOBAL GENERICS 39% Bovvoy 5% Q0Q Br4s%vor 5% Qoa* > 28,506 cr a a 920% YoY" H2%Q00%* PSAI - 11% 7 15% OTHERS 21,305 cr 0.
Slide 7: FY25: Double-digit growth across geographies
FY25 : Double-digit growth across geographies FY25 REVENUE BY SEGMENT GLOBAL GENERICS SPLIT IN FY25 214,516 cr = 3,588* cr North America Europe GLOBAL GENERICS _. 89% Pr2xyYor Brs%Yoy" > 232,554 or “) ta B17% YoY" PSAI 17% OTHERS 25,373 cr 1% India BD 16%yYoY = 28,955 cr 23,385 cr Global Generics r:
Slide 8: Investing and upscaling commercial and R&D capabilities
Investing and upscaling commercial and R&D capabilities GROSS MARGINS (% of Revenues) SG&A EXPENSES (% of Revenues) R&D EXPENSES ( °f Revenues) Q4FY25 NN 55.5°% Q4FY25 Sy 28.5°% O4FY25 NN 65°), Q3FY25 58.7% Q3FY25 28.9% QsFY25 8.0% Q4FY24 58.6% Q4FY24 28.9% Q4FY24 9.7% CAPEX «cr FREE CASH FLOW «c» N
Slide 9: North America: Demand-led growth offset by price erosion
North America Demand-led growth offset by price erosion Q4FY25 Performance iia ‘ciiaiiiaiieaees | Gt 93.9%Vs.38% = = 7 ae | 3 iIncludes 46 Para IVs & 20 FTFs Revenues 23,559 cr 9%YoY 5% QoQ GROWTH DRIVERS New launches, product specific opportunities, : STAB LE offset by price erosion : (for m manufa
Slide 10: India
India Q4FY25 Performance | #8.4% vs. 8.0% Revenues 21,305 cr 16%YOY 3% QoQ ROWTH DRIVERS YoY: New product : 40th launches, incl. in-licensed : vaccine portfolio from Sanofi and price increase QoQ: Slower than expected growth in certain TAs like Gastro, Cardio, & Pain. Growing in double digits, new p
Slide 11: Emerging Markets
Emerging Markets Q4FY25 Performance Revenues 21,398 cr 16% YOY 3% QoQ GROWTH DRIVERS * YoY: New launches & higher volumes in base business QoQ: Lower volumes New launches & higher sales volumes drive double-digit growth REVENUE SPLIT cISR 17% RoW 36% Russia 47% SSUES AS Der Con: 2655 cr @ sivvor ¥ 7
Slide 12: Europe: Base business growth aided by acquired NRT business revenues
Base business growth aided by acquired NRT business revenues Europe Q4FY25 REVENUE SPLIT Performance a 2597 cr B 1% a0 ts Integration of 1st country, UK, : ted 355 i : of countries to be o z cr i - Nordics Revenues France, Italy, Acquired @ 2w%YY B7™% 20a : cD Oilers NRT sgesseasoesse ORR 21,275* cr
Slide 13: PSAI: Growth led by new launches and higher API volumes
PSAI Growth led by new launches and higher API volumes as well Q4FY25 as growth in services business Performance CP Revenues 2956 cr 16%YOY 16% QoQ co 26.3% 27.1% » 62 411 GROWTH DRIVERS API growth driven by new launches & higher volumes. Growth in CDMO. business Its "AS per cc fing nts under IFRS
Slide 14: In Summary
In Summary A diversified business model with broad based levers
Slide 15: About key metrics and non-GAAP Financial Measures
About key metrics and non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are a
Slide 16: Dr.Reddy’s QS
Dr.Reddy’s QS mee
DR Reddys Laboratories — Q4 FY2025 Earnings Presentation on 6ix